Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts

被引：0
|
作者：
Jelas, I [1 ]
de Bortoli, T. [2 ]
Benary, M. [2 ]
Horak, P. [3 ]
Lamping, M. [2 ]
Schaefer, R. [2 ]
Klauschen, F. [2 ]
Tinhofer-Keilholz, I [2 ]
Leyvraz, S. [2 ]
Keller, U. [2 ]
Stenzinger, A.
Froehling, S. [3 ]
Stintzing, S. [1 ,4 ]
Kurzrock, R. [5 ]
Keilholz, U. [2 ]
Rieke, D. [2 ]
机构：
[1] Charite Univ Med Berlin, Klin Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] NCT Heidelberg, Heidelberg, Germany
[4] Univ Klinikum Heidelberg, Heidelberg, Germany
[5] Worldwide Innovat Network WIN Assoc WIN Consortiu, Villejuif, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V563
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [31] An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker
    Yaocheng Yang
    Xianzhe Tang
    Zhengjun Lin
    Tao Zheng
    Sheng Zhang
    Tang Liu
    Xiaolun Yang
    European Journal of Medical Research, 28
  • [32] Dynamics of predicted tumor neoepitope burden in a pan-cancer solid tumor pediatric cohort
    Macaulay, Charles W.
    Breese, Marcus R.
    Sweet-Cordero, E. Alejandro
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (12)
  • [33] Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
    Xu, Peiyi
    Zhang, Qiuyan
    Zhai, Jing
    Chen, Pu
    Deng, Xueting
    Miao, Lin
    Zhang, Xiuhua
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [34] Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy
    Sung, Winnie W. Y.
    Chow, James C. H.
    Cho, William C. S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (02) : 141 - 143
  • [35] Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed
    Meng, Xiang-Yu
    Wu, Qiu-Ji
    EPIGENOMICS, 2023, 15 (22) : 1175 - 1178
  • [36] A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
    Tian, Yanhua
    Xu, Jiachen
    Chu, Qian
    Duan, Jianchun
    Zhang, Jianjun
    Bai, Hua
    Yang, Zhenlin
    Fang, Wenfeng
    Cai, Liangliang
    Wan, Rui
    Fei, Kailun
    He, Jie
    Gao, Shugeng
    Zhang, Li
    Wang, Zhijie
    Wang, Jie
    BMC MEDICINE, 2020, 18 (01)
  • [37] Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis
    Disel, Umut
    Sivakumar, Smruthy
    Pham, Tim
    Fleischmann, Zoe
    Anu, R., I
    Sokol, Ethan S.
    Kurzrock, Razelle
    ONCOLOGIST, 2024, 29 (02) : e213 - e223
  • [38] Use of CRTAM expression as a predictive biomarker for immune checkpoint blockade in a pan-cancer cohort
    Miyashita, Hirotaka
    Nishizaki, Daisuke
    Lee, Suzanna
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Aoshima, Ken
    Kato, Shumei
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] The comprehensive potential of AQP1 as a tumor biomarker: evidence from kidney neoplasm cohorts, cell experiments and pan-cancer analysis
    Liu, Yifan
    Lyu, Donghao
    Yao, Yuntao
    Cui, Jinming
    Liu, Jiangui
    Bai, Zikuan
    Zhao, Zihui
    Li, Yuanan
    Lu, Bingnan
    Dong, Keqin
    Pan, Xiuwu
    HUMAN GENOMICS, 2025, 19 (01)
  • [40] Identification of a predictive biomarker for liposomal nanoparticle delivery through pan-cancer pooled screening
    Straehla, Joelle P.
    Boehnke, Natalie
    Safford, Hannah
    Kocak, Mustafa
    Rees, Matthew G.
    Ronan, Melissa
    Rosenberg, Danny
    Adelmann, Charles H.
    Chivukula, Raghu R.
    Cheah, Jaime H.
    Li, Hojun
    Roth, Jennifer A.
    Koehler, Angela N.
    Hammond, Paula T.
    CANCER RESEARCH, 2022, 82 (12)
12345